Related Experiment Video
Updated: Jun 29, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Common and contrasting genomic profiles among the major human lung cancer subtypes
G Tonon1, C Brennan, A Protopopov
1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115 , USA.
Abstract:
Lung cancer is the leading cause of cancer mortality worldwide. With the recent success of molecularly targeted therapies in this disease, a detailed knowledge of the spectrum of genetic lesions in lung cancer represents a critical step in the development of additional effective agents. An integrated high-resolution survey of regional amplifications and deletions and gene expression profiling of non-small-cell lung cancers (NSCLC) identified 93 focal high-confidence copy number alterations (CNAs), with 21 spanning less than 0.5 Mb with a median of five genes. Most CNAs were novel and included high-amplitude amplification and homozygous deletion events. Pathogenic relevance of these genomic alterations was further reinforced by their recurrence and overlap with focal alterations of other tumor types. Additionally, the comparison of the genomic profiles of the two major subtypes of NSCLC, adenocarcinoma (AC) and squamous cell carcinoma (SCC), showed an almost complete overlap with the exception of one amplified region on chromosome 3, specific for SCC. Among the few genes overexpressed within this amplicon was p63, a known regulator of squamous cell differentiation. These findings suggest that the AC and SCC subtypes may arise from a common cell of origin and they are driven to their distinct phenotypic end points by altered expression of a limited number of key genes such as p63.
Insights
Researchers mapped genetic changes in non-small cell lung cancer (NSCLC), identifying novel copy number alterations (CNAs). These genomic insights, particularly a SCC-specific amplification involving p63, advance understanding of lung cancer subtypes.
Area of Science:
- Genomics
- Oncology
- Molecular Biology
Background:
- Lung cancer remains a leading cause of cancer mortality globally.
- Molecularly targeted therapies have shown promise, necessitating deeper understanding of lung cancer's genetic landscape.
- Identifying genetic lesions is crucial for developing new and effective lung cancer treatments.
Purpose of the Study:
- To conduct a comprehensive, high-resolution survey of regional copy number alterations (CNAs) and gene expression in non-small cell lung cancer (NSCLC).
- To identify and characterize novel focal amplifications and deletions in NSCLC.
- To compare the genomic profiles of adenocarcinoma (AC) and squamous cell carcinoma (SCC) subtypes of NSCLC.
Main Methods:
- Integrated high-resolution survey of regional amplifications and deletions.
- Gene expression profiling of non-small cell lung cancer (NSCLC) samples.
- Comparative genomic analysis of AC and SCC subtypes.
Main Results:
- Identified 93 focal high-confidence copy number alterations (CNAs), including 21 small events ( < 0.5 Mb) with a median of five genes.
- Discovered numerous novel CNAs, including high-amplitude amplifications and homozygous deletions, with pathogenic relevance supported by recurrence and overlap with other tumor types.
- Found an almost complete overlap in genomic profiles between AC and SCC, except for a specific amplified region on chromosome 3 in SCC, which overexpresses p63.
Conclusions:
- The study identified novel genomic alterations in NSCLC, providing critical insights for targeted therapy development.
- The findings suggest that AC and SCC may originate from a common cell type.
- Distinct phenotypic endpoints of AC and SCC are likely driven by the altered expression of key genes, such as p63 in SCC.
